Biogen this week announced Paul McKenzie's new position as EVP of Pharmaceutical Operations &
Technology, joining the Biogen management team under the leadership of CEO George
Scangos.
“With his extensive technical and development expertise, we believe Paul is ideally suited to lead the next phase of growth across Biogen’s development and manufacturing operations,” Scangos said. “He will play an essential role, building upon our tradition of world-class manufacturing while leading the development of next-generation capabilities to ensure global availability of our current and future therapies.”
McKenzie adds a wide range of experience to the Biogen team. He previously held several leadership positions at Johnson & Johnson, Janssen, Bristol-Myers Squibb and Merck. In his new position, McKenzie will lead the operations and technology organization and oversee the construction of the Solothurn, Switzerland, advanced biologics manufacturing facility.
“This is an exciting time to be at Biogen, and I am honored to take the reins of pharmaceutical operations and technology from John Cox, who has been instrumental in creating one of the best teams in the industry and driving leading-edge innovation and operations for our clinical and commercial portfolio,” McKenzie said. “Our team will continue to build on a very successful track record of safety, quality and reliability to advance our diverse portfolio in biologics, oligonucleotides, gene therapy and small molecules.”
Last month Cox was named CEO of a new Biogen spin-off company dedicated to advancing treatments for hemophilia.
Alerts Sign-up